Hydration Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Oliver Baker
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 28.1% |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$1m | US$341k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$347k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$11m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$300k | -US$9m |
Compensation vs Market: Oliver's total compensation ($USD1.21M) is above average for companies of similar size in the Australian market ($USD297.98K).
Compensation vs Earnings: Oliver's compensation has been consistent with company performance over the past year.
CEO
Oliver Baker
no data
Tenure
US$1,211,091
Compensation
Mr. Oliver Baker is Chief Executive Officer of The Hydration Pharmaceuticals Company Limited. Mr. Baker is the CEO of Hydralyte North America, having joined the business in 2018, taking responsibility for...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Director | 2.8yrs | US$51.39k | 0.12% A$ 6.3k | |
| Non-executive Director | less than a year | no data | no data | |
| Non-Executive Director | 6.1yrs | US$45.86k | 0.84% A$ 43.6k |
2.8yrs
Average Tenure
Experienced Board: HPC's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.